Form 4: ImmuCell CEO Boosts Stake with Open Market Purchases
Insider Trading Report
ImmuCell's President and CEO, Paul Francis Olivier te Boekhorst, acquired additional common stock through open market purchases in early December 2025.
Summary
- Paul Francis Olivier te Boekhorst, President and CEO, and a Director of ImmuCell Corp (ICCC), reported acquiring common stock.
- On December 2, 2025, 3,708 shares of common stock were purchased at a price of $4.8686 per share.
- On December 3, 2025, two separate purchases were made: 2,556 shares at $5.003 per share and 3,521 shares at $5.0406 per share.
- These transactions increased Mr. te Boekhorst's direct beneficial ownership to 9,785 shares of common stock.
- The transactions were made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading strategy.
Sentiment
Score: 8
Explanation: The sentiment is highly positive due to significant insider buying by the CEO, which signals strong management confidence in the company's future performance and valuation.
Positives
- The President and CEO's open market purchases demonstrate strong confidence in the company's future prospects and valuation.
- Increased insider ownership aligns management's interests more closely with those of shareholders.
- The use of a Rule 10b5-1 plan suggests a disciplined, pre-planned approach to stock acquisition, rather than reactive trading.
Future Outlook
NA
Industry Context
Insider buying, particularly by a CEO, is generally viewed by the market as a positive signal, indicating that those with the most intimate knowledge of a company believe its stock is undervalued or poised for future growth. This action by ImmuCell's CEO suggests a belief in the company's strategic direction and operational performance within its industry.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Trading Plan Disclosure | The reported transactions were executed pursuant to a Rule 10b5-1(c) plan, which allows insiders to set up a pre-arranged plan for buying or selling company stock to avoid accusations of insider trading. | NA | This indicates a structured and compliant approach to insider trading, enhancing transparency and reducing potential concerns about opportunistic trading. |
Stakeholder Impact
- Shareholders: The increased stake by the CEO can instill greater confidence among existing and potential shareholders, suggesting strong internal belief in the company's value proposition and future growth.
- Employees: May view the CEO's investment as a positive sign of stability and future success for the company.
Key Dates
| Date | Description |
|---|---|
| 12/02/2025 | Acquisition of 3,708 shares of common stock by Paul Francis Olivier te Boekhorst. |
| 12/03/2025 | Acquisition of 2,556 shares and 3,521 shares of common stock by Paul Francis Olivier te Boekhorst. |
| 12/03/2025 | Date of filing of the Statement of Changes in Beneficial Ownership (Form 4). |
Recommendation
buyThe significant open market purchases by ImmuCell's President and CEO, Paul Francis Olivier te Boekhorst, represent a strong vote of confidence in the company's intrinsic value and future prospects. Insider buying, especially from top executives, often precedes positive operational or financial developments. This action, coupled with the use of a Rule 10b5-1 plan, suggests a deliberate and strategic investment decision, making ImmuCell's stock an attractive 'buy' for investors seeking companies with strong insider alignment and perceived undervaluation.
Keywords
ImmuCell, ICCC, Insider Buying, CEO Stock Purchase, Beneficial Ownership, Equity Acquisition, Paul te Boekhorst, Rule 10b5-1, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.